title: Cold oxygen plasma technology efficiency against different airborne respiratory viruses.
abstract: BACKGROUND
  Respiratory infections caused by viruses are major causes of upper and lower respiratory tract infections. They account for an important mortality and morbidity worldwide. Amongst these viruses, influenza viruses and paramyxoviruses are major pathogens. Their transmission is mainly airborne, by direct transmission through droplets from infected cases.
  
  
  OBJECTIVE
  In the context of an influenza pandemic, as well as for the reduction of nosocomial infections, systems that can reduce or control virus transmission will reduce the burden of this disease. It may also be part of the strategy for pandemic mitigation.
  
  
  METHODS
  A new system based on physical decontamination of surface and air has been developed. This process generates cold oxygen plasma (COP) by subjecting air to high-energy deep-UV light. To test its efficiency, we have developed an experimental device to assess for the decontamination of nebulized respiratory viruses. High titer suspensions of influenza virus type A, human parainfluenza virus type 3 and RSV have been tested.
  
  
  RESULTS
  Different experimental conditions have been evaluated against these viruses. The use of COP with an internal device allowed the best results against all viruses tested. We recorded a reduction of 6.5, 3.8 and 4 log(10) TCID50/mL of the titre of the hPIV-3, RSV and influenza virus A (H5N2) suspensions.
  
  
  CONCLUSIONS
  The COP technology is an efficient and innovative strategy to control airborne virus dissemination. It could successfully control nosocomial diffusion of respiratory viruses in hospital setting, and could be useful for the reduction of influenza transmission in the various consultation settings implemented for the management of cases during a pandemic.
authors.affiliation: Université de Lyon, F-69000 Lyon, France.
authors.forename: O
authors.initials: O
authors.lastname: Terrier
authors.forename: B
authors.initials: B
authors.lastname: Essere
authors.forename: M
authors.initials: M
authors.lastname: Yver
authors.forename: M
authors.initials: M
authors.lastname: Barthélémy
authors.forename: M
authors.initials: M
authors.lastname: Bouscambert-Duchamp
authors.forename: P
authors.initials: P
authors.lastname: Kurtz
authors.forename: D
authors.initials: D
authors.lastname: VanMechelen
authors.forename: F
authors.initials: F
authors.lastname: Morfin
authors.forename: G
authors.initials: G
authors.lastname: Billaud
authors.forename: O
authors.initials: O
authors.lastname: Ferraris
authors.forename: B
authors.initials: B
authors.lastname: Lina
authors.forename: M
authors.initials: M
authors.lastname: Rosa-Calatrava
authors.forename: V
authors.initials: V
authors.lastname: Moules
mesh_terms: D000818:Animals; D002460:Cell Line; D004202:Disinfectants / Q000494:pharmacology*; D004203:Disinfection / Q000379:methods*; D004285:Dogs; D004783:Environmental Microbiology; D000882:Haplorhini; D053125:Influenza A Virus, H5N2 Subtype / Q000187:drug effects*; D050296:Microbial Viability / Q000187:drug effects*; D010100:Oxygen / Q000494:pharmacology*; D010224:Parainfluenza Virus 3, Human / Q000187:drug effects*
chemical_list: D004202:Disinfectants; D010100:Oxygen